Khondrion, a Nijmegen, the Netherlands-based clinical-stage biopharmaceutical firm growing therapies for main mitochondrial illness (PMD), obtained an Innovation Credit score of as much as €5M from the Netherlands Enterprise Company.
This authorities funding, matched by an funding from personal backers, will fund Wave 1 of the corporate’s pivotal Section 3 scientific trial of sonlicromanol. Sonlicromanol is a first-in-class small-molecule candidate remedy for m.3243A>G PMD, the most typical genetic type of mitochondrial illness. The Section 3 trial is predicted to launch in H2-2025, marking a milestone in Khondrion’s mission to ship the first authorized therapy for these issues.
The corporate intends to allocate the quantity for the Wave 1 of its pivotal Section 3 scientific trial of sonlicromanol.
Based by Jan Smeitink, Khondrion is a clinical-stage pharmaceutical firm discovering and growing therapies concentrating on mitochondrial illness. Its Lead pipeline asset, KH176, is a possible oral small molecule in part IIb scientific improvement to deal with a spread of mitochondrial illnesses. It has been granted Orphan Drug Designation for MELAS (mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes) spectrum issues and Leigh illness in Europe and for all inherited mitochondrial respiratory chain issues within the US.
The corporate work in collaboration with affected person organisations internationally in addition to a world scientific and educational community to speed up the invention and improvement of its potential medicines for sufferers with mitochondrial illnesses
FinSMEs
06/05/2025
